Incyte (INCY) Hisse Fiyat
Incyte Fiyat
Incyte, son 19 yılda gelirini yıllık %31,7 artırarak 5,14 Md USD seviyesine taşıdı. Hisse başına kâr, son 10 yılda yıllık %68,6 büyüdü. Incyte için net marj, %25,0 ile birkaç yıl önceki %31,8 seviyesine göre geriledi. Incyte için 12 aylık konsensüs fiyat hedefi 130,00 USD; bu, hissenin bugünkü fiyatının yaklaşık %15,4 üzerinde bir seviyeye denk geliyor. 35 analistten 18 tanesi hisse için alım öneriyor — genel konsensüs: Al.
Incyte hisse senedi fiyatı
Incyte iş modeli ve hisse analizi
Incyte hakkında sık sorulan sorular
The business model of Incyte Corp revolves around discovering, developing, and commercializing novel medicines to address the needs of patients with serious diseases. As a leading biotechnology company, Incyte focuses on discovering and developing small molecule drugs that target specific biological pathways involved in diseases such as cancer and immune-inflammatory disorders. By leveraging its expertise in genomics and medicinal chemistry, Incyte aims to bring innovative treatments to market, improving patients' lives worldwide. Through collaborations and partnerships, Incyte also strives to expand its product portfolio and accelerate its pipeline of promising therapies.
Incyte Corp is primarily active in the biotechnology and pharmaceutical industries.
The main competitors of Incyte Corp in the market are Bristol-Myers Squibb Company, Novartis AG, and Merck & Co., Inc.
Incyte Corp is a leading biopharmaceutical company based in the United States. Founded in 1991, it has established a strong reputation in the field of drug discovery and development. Incyte Corp primarily focuses on the discovery, development, and commercialization of innovative therapies to address various unmet medical needs. Throughout its history, the company has been committed to advancing scientific knowledge, and it has successfully launched several drugs targeting different diseases. With a dedicated team of researchers and professionals, Incyte Corp continues to make significant contributions to the healthcare industry, aiming to improve the lives of patients worldwide.
Incyte Corp has achieved several significant milestones in its history. One notable achievement is the development and approval of its flagship drug, Jakafi® (ruxolitinib), by the U.S. Food and Drug Administration (FDA) in 2011. Jakafi® is the first and only FDA-approved treatment for certain types of rare blood cancers. Additionally, Incyte Corp has made advancements in the field of oncology with the discovery and development of multiple innovative drugs, aiming to improve the lives of patients with various types of cancer. The company continues to expand its pipeline and collaborate with leading research institutions, further establishing itself as a prominent player in the biopharmaceutical industry.
Incyte Corp is primarily present in various countries and regions globally. The company has a widespread presence in the United States, where its headquarters are located in Wilmington, Delaware. Additionally, Incyte Corp has established its significant presence in Europe, including countries such as the United Kingdom, Germany, France, Italy, and Spain. It has also expanded its operations in Asia-Pacific regions like Japan, China, and Singapore. Furthermore, Incyte Corp has been expanding its reach in Latin American countries such as Brazil and Mexico, as well as in Canada. Overall, Incyte Corp has a strong international presence, allowing it to cater to a global market.
Incyte Corp represents values centered around innovation, collaboration, and integrity. The company prioritizes scientific excellence and is dedicated to discovering and developing transformative medicines for patients. Incyte Corp fosters a corporate philosophy that emphasizes the importance of putting patients first, embracing diversity and inclusion, and maintaining high ethical standards. With a focus on research and development, Incyte Corp strives to make a positive impact on the lives of patients and the healthcare industry as a whole.
Analistler şu anda Incyte hissesi için ortalama 128,38 USD hedef fiyat belirliyor (medyan: 130,00 USD); bu, son fiyata göre +14,0 % anlamına gelir. Konsensüs 35 analist notuna dayanır.
35 analist şu anda Incyte hissesini değerlendiriyor: 18 al, 17 tut, 0 sat öneriyor. 2026 için analistler Incyte şirketinin 5,94 Md USD gelir ve 3,41 USD hisse başına kâr üretmesini bekliyor.
Güncel döviz kuruyla Incyte hissesi 100,50 EUR (112,61 USD) seviyesindedir.
Incyte hissesi (INCY) 8 borsada işlem görür, bunlar arasında: NASDAQ (INCY), London (0J9P.L), SIX (Zürich) (ICY.SW), Frankfurt (ICY.F), München (ICY.MU), Düsseldorf (ICY.DU).
Incyte Corp is a biopharmaceutical company that focuses on the discovery, development, and marketing of drugs to help patients with serious diseases. The company is headquartered in Wilmington, Delaware, USA, and operates subsidiaries in Europe and Asia. Its business model is based on developing therapies to combat serious diseases such as cancer, inflammation, and autoimmune diseases through targeted therapy that attacks specific molecules in the body to reduce tumor spread or inflammatory reactions. Incyte Corp has a wide range of products that treat various diseases, with its flagship product being Jakafi® (Ruxolitinib), a drug for treating myelofibrosis and polycythemia vera. It also has a strong pipeline of new drugs in development, including Itacitinib for treating graft-versus-host disease and INCMGA00012 for treating solid tumors. The company is investing in digitization and data analysis to optimize its research and development efforts, and has various business segments including research and development, sales and marketing, clinical studies, and others. It distributes its products directly to clinics and hospitals as well as indirectly through wholesalers and distribution partners, and has formed partnerships with other companies in the industry to enhance research and development and expand global market access. In summary, Incyte Corp is dedicated to discovering, developing, and marketing drugs for patients with serious diseases, with a broad product range, strong partnerships, and a pipeline of new drugs in development. The company is dedicated to using data to improve patient care.
beklenen'nin Incyte hasılatı 5,94 Md USD'dir. Bu rakam, mevcut finansal verilere dayanmakta ve şirketin iş performansını yansıtmaktadır.
beklenen'nin Incyte karı 697,46 M USD'dir. Net kar, tüm giderleri düştükten sonra şirketin kârlılığını gösterir.
Incyte'nin Fiyat/Kazanç (F/K) oranı şu anda 33,06'dir. F/K oranı, cari hisse fiyatını hisse başına kazançla karşılaştırır ve yatırımcıların Incyte hisse senedinin değerlemesini değerlendirmelerine yardımcı olur.
Incyte'nin Fiyat/Satış (F/S) oranı şu anda 3,88'dir. F/S oranı, pazar kapitalizasyonunu yıllık gelirle karşılaştırır ve Incyte hisse senedinin değerleme metriği olarak hizmet eder.
Incyte'nin Eulerpool Kalite Puanı 6/10'dur.
Incyte'nin ISIN'i US45337C1027'dir. ISIN (Uluslararası Menkul Kıymetler Kimlik Numarası), menkul kıymetler için küresel olarak benzersiz bir tanımlayıcıdır.
Incyte'nin WKN'i 896133'dir. WKN (Wertpapierkennnummer), menkul kıymetleri tanımlamak için kullanılan altı haneli bir Alman kimlik numarasıdır.
Incyte'nin ticker'ı INCY'dir. Ticker sembolü, Incyte hisseleri borsada işlem görmek için kullanılır.
Incyte Hissesi
Incyte Emsaller Grubu
Incyte Ticker
Incyte FIGI
Incyte'nin tüm temel göstergeleri ve derinlemesine analizi
Incyte hissesine yönelik aktienanalizimiz, satış, kar, P/E oranı, P/S oranı, EBIT gibi önemli mali kriterleri içermekte olup, dividende bilgilerini de ele almaktadır. Ayrıca, hisseler, piyasa değeri, borçlar, özsermaye ve Incyte şirketin yükümlülükleri gibi konuları incelemekteyiz. Bu konular hakkında daha detaylı bilgilere ihtiyacınız varsa, web sitemizin alt sayfalarında kapsamlı analizler sunuyoruz: